Focal epilepsy
MONDO:0005384A seizure caused by a localized disorder.
Also known as: focal epilepsy, partial epilepsy
141 clinical trials for this condition and its sub-types, 101 tagged with Focal epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Focal epilepsy
-
Familial partial epilepsy 0 trials · 39 incl. sub-types
7 sub-types
- Temporal lobe epilepsy 31 trials Sub-types →
- Mesial temporal lobe epilepsy with hippocampal sclerosis 10 trials
- Self-limited epilepsy with centrotemporal spikes 3 trials Sub-types →
- Generalized epilepsy-paroxysmal dyskinesia syndrome 1 trial
- Autosomal dominant epilepsy with auditory features 0 trials
- Familial focal epilepsy with variable foci 0 trials Sub-types →
- Familial sleep-related hypermotor epilepsy 0 trials Sub-types →
-
Frontal lobe epilepsy 5 trials
2 sub-types
- Primary motor cortex epilepsy 0 trials
- Sleep-related hypermotor epilepsy 0 trials Sub-types →
-
Childhood-onset self-limited focal epilepsy syndrome 0 trials · 3 incl. sub-types
4 sub-types
-
Partial motor epilepsy 1 trial
-
1 sub-type
-
Complex partial epilepsy 0 trials
-
Partial sensory epilepsy 0 trials
-
Simple partial epilepsy 0 trials
-
4 sub-types
Most studied deeper sub-types
-
Brain implant study aims to cut seizures in epilepsy patients
Disease control Stopped earlyThis study tested a brain implant (deep brain stimulation) to reduce seizures in 29 adults with epilepsy whose seizures were not controlled by medication. Participants kept diaries to track seizure frequency over three years. The goal was to see if the device safely and effective…
Sponsor: MedtronicNeuro • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Seizure drug study ends early – safety results awaited
Disease control Stopped earlyThis study looked at the long-term safety of an experimental drug called CVL-865 in adults whose focal seizures were not controlled by other medications. About 105 people who completed a previous trial took CVL-865 alongside their usual seizure drugs for up to 57 weeks. The study…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC